在复杂的尿路感染中使用Cefepime-Taniborbactam
Florian M Wagenlehner1, Leanne B Gasink1, Paul C McGovern1
1From Justus Liebig University, Giessen, Germany (F.M.W.); LBG Consulting, Philadelphia (L.B.G.), and Venatorx Pharmaceuticals, Malvern (P.C.M., G.M., M.D., T.H.) - both in Pennsylvania; Fortrea, Burlington, NC (P.M.); and DaneStat Consulting, Macclesfield, United Kingdom (A.D.).
The New England journal of medicine
|February 14, 2024
概括
塞费皮姆-坦尼博巴克坦在治疗复杂的尿路感染,包括急性肌炎方面,与美罗相比,具有更高的疗效. 这种新型组合疗法提供了一个有前途的替代方案,具有可比的安全性.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 耐卡巴尼姆的肠道细菌和耐多药的空气虫 (Pseudomonas aeruginosa) 对全球健康构成重大威胁.
- 塞菲皮姆-塔尼博巴克坦是一种正在研究中的抗生素组合,针对这些耐药病原体.
研究的目的:
- 评估Cefepime-taniborbactam的疗效和安全性,与入院成年人患有复杂尿路感染 (cUTI) 的梅罗相比.
主要方法:
- 第三阶段,双盲,随机试验比较静脉注射cefepime-taniborbactam与cUTI患者中的meropenem.
- 主要结局:微生物治疗意向 (microITT) 群体中的复合成功 (微生物和临床).
- 患者每8小时接受研究药物7天,可延长到14天的细菌性血.
主要成果:
- 在微型ITT群体中,Cefepime-taniborbactam的复合成功率 (70.6%) 与meropenem (58.0%) 相比,在微型ITT群体中取得了更高的成功率 (P=0.009).
- 在后期随访中,有利于塞费皮姆-塔尼博巴克坦的治疗差异仍然存在.
- 两组之间不良事件的发生率相似,严重不良事件没有显著差异.
结论:
- 塞菲皮姆-坦尼博巴克坦在治疗复杂的尿路感染,包括急性肺炎方面优于美罗.
- 塞费皮姆-坦尼博巴克坦的安全性概况与梅罗相似.
- 这项研究支持cefepime-taniborbactam作为对抗性细菌感染的潜在新疗法.
相关概念视频
01:27Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
01:28Pneumonia IV: Management
327
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
327
01:15Drug Elimination by Renal Route: Tubular Secretion
2.4K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.4K
01:28Pulmonary Tuberculosis V
180
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
180